Takeda announces china nmpa approval of livtencity® (maribavir) for the treatment of adults with post-transplant cytomegalovirus (cmv) refractory to prior therapies

Osaka, japan & cambridge, massachusetts--(business wire)--takeda (tse:4502/nyse:tak) today announced that livtencity® (maribavir) has been approved by the national medical products administration (nmpa) of china for the treatment of adult patients with post-hematopoietic stem cell transplant (hsct) or solid organ transplant (sot) cytomegalovirus (cmv) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.
TAK Ratings Summary
TAK Quant Ranking